Takeda Pharmaceuticals Agrees to Pay 13.6 Million to Resolve False Claims Allegations

Takeda Pharmaceuticals U.S.A. Inc. has agreed to pay $13,670,921 to resolve allegations that it knowingly caused the submission of false claims to Medicare and other federal health care programs, the Justice Department announced on May 14, 2026.

The company, which markets and sells Trintellix to treat major depressive disorder, allegedly paid kickbacks to healthcare providers to induce them to prescribe the antidepressant. Federal health care programs affected include Medicare, which covers more than 65 million beneficiaries, and other payers such as Medicaid.

The settlement covers claims submitted over a multiyear period although the exact volume of prescriptions or claims was not detailed in the release.

The agreement resolves the matter without Takeda admitting liability. Prior to the settlement the company faced potential continued exposure to False Claims Act liability, including treble damages and per-claim penalties. The new state eliminates that exposure in exchange for the fixed payment, which is due as part of the resolution. The settlement takes effect immediately upon execution.

Downstream, Takeda must update its compliance programs to prevent future inducements tied to federal program reimbursements. The Department of Health and Human Services Office of Inspector General can impose heightened scrutiny or exclusion if similar conduct recurs.

Federal health programs will recover the $13.6 million, which can be redirected to program integrity efforts or beneficiary services. Prosecutors in the Eastern District of California, which handled the investigation, close this file but retain authority to pursue related cases involving other manufacturers or providers.

This settlement continues a series of DOJ enforcement actions targeting pharmaceutical kickbacks to influence prescribing behavior under the False Claims Act. The department has recovered billions through similar resolutions in recent years. The case was brought under the qui tam provisions of the False Claims Act, which allow whistleblowers to initiate suits on behalf of the government.

Primary sources: U.S. Department of Justice